April 7 (Reuters) - OS Therapies Inc OSTX.A:
OS THERAPIES REQUESTS MEETING WITH FDA TO GAIN AGREEMENT ON SURROGATE ENDPOINT$(S)$ FOR BREAKTHROUGH THERAPY DESIGNATION & ACCELERATED APPROVAL OF OST-HER2 IN THE PREVENTION OF RECURRENCE OF FULLY RESECTED, LUNG METASTATIC OSTEOSARCOMA
OS THERAPIES: APPLIES FOR MEETING PER FDA SUGGESTION RECEIVED ON APRIL 2, 2025
OS THERAPIES -SUFFICIENT CASH ON HAND TO OPERATE INTO MID-2026
OS THERAPIES: MEETING IS EXPECTED TO OCCUR IN Q2 OF 2025
OS THERAPIES: INTENDS TO INITIATE ROLLING BLA SUBMISSION WITH POTENTIAL TO GET ACCELERATED APPROVAL AS EARLY AS YEAR-END 2025
Source text: ID:nBw21PR7wa
Further company coverage: OSTX.A
(((( Reuters.briefs@thomsonreuters.com ;));))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。